Method for manufacturing spray-type hemostatic agent mixed with kaolin and cellulose, and spray-type hemostatic agent manufactured thereby

Abstract

The present invention relates to a method for manufacturing a spray-type hemostatic agent mixed with kaolin and cellulose, and a spray-type hemostatic agent manufactured thereby. The method comprises the steps of: adding hyaluronic acid to sterile distilled water; adding lecithin to the mixture; adding kaolin and cellulose to the mixture; cooling the mixture; injecting the mixture into a spray-type container; and filling the container with gas. Due to being mixed with hyaluronic acid and lecithin in addition to kaolin and cellulose, the present invention is excellent in terms of re-bleeding prevention rate, absorption rate, and applicability, has excellent tissue protection and infection prevention effects on a wound surface compared to conventional injection and gel types, and can prevent situations where patients are at risk due to excessive bleeding.

Description

Method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose and a spray-type hemostatic agent manufactured thereby

[0001] The present invention relates to a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose, and to a spray-type hemostatic agent manufactured thereby. More specifically, the present invention relates to a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose, which can be used by spraying immediately in an emergency situation and effectively acts on a bleeding site, and which has excellent hemostatic action and hemostatic effect, and to a spray-type hemostatic agent manufactured thereby.

[0002] Various hemostatic agents are being developed to stop bleeding and save lives. Various types of hemostatic agents, including topical hemostatic agents, intravenous hemostatic agents, and surgical hemostatic agents, are used depending on the situation. They are available in various forms, including bandages, powders, gels, and injections, and work to stop bleeding through various mechanisms, including platelet activation, clotting factor activation, and fibrin network formation.

[0003] Hemostatic agents contain various ingredients that enhance the body's natural hemostasis process. Collagen provides a scaffold that promotes platelet adhesion and aggregation, which are crucial for clot formation. Gelatin absorbs blood and body fluids, swelling to form a physical barrier. Gelatin can absorb up to 45 times its own weight in blood. Cellulose forms a gel-like clot upon contact with blood, creating a barrier. Chitosan, derived from chitin, promotes blood clotting by promoting the aggregation of red blood cells and platelets. Thrombin is an enzyme that converts fibrinogen to fibrin, forming a stable clot. Kaolin is a soft, white or nearly white clay found in nature, composed primarily of minerals such as aluminum and silicon. Kaolin is widely used in medical applications to promote blood clotting and control bleeding, particularly by activating factor XII, a key protein in the coagulation pathway, which initiates the clotting process more quickly and effectively. Kaolin is considered a safe and effective hemostatic agent. By preventing foreign proteins from entering the body, the risk of an adverse immune response is reduced. Kaolin is an essential component of modern hemostatic agents due to its ability to effectively and safely promote coagulation.

[0004] Hemostatic agents such as the above are important in both surgical and emergency situations to control bleeding and ensure patient stability.

[0005] However, conventional injectable and gel-type hemostatic agents containing these ingredients have various problems and limitations.

[0006] Patent Publication No. 10-2023-0057168 (Hemostatic composition comprising keratin-bound fibrinogen hydrogel as an active ingredient) is characterized by being activated without loss of blood coagulation components through physical action.

[0007] Patent Publication No. 10-2023-0057168 requires specific conditions and techniques for applying the hemostatic agent, which can make its use more complex. In emergency situations where time and simplicity are critical, this complexity can hinder the effective and timely application of the hemostatic agent.

[0008] For these injectable and gel-type hemostatic agents, accurately identifying the bleeding site and effectively administering the agent can be challenging. This difficulty is exacerbated in cases of internal bleeding or complex wounds where the source of bleeding is not readily visible or accessible.

[0009] Precisely controlling the dosage of injectable hemostatic agents is difficult. Gel-based preparations offer better dosage control, but can be difficult to apply evenly to the bleeding site, which can reduce their effectiveness.

[0010] Injectable and gel-type hemostatic agents often face usability issues, such as long application times and limited use in specific areas. These factors can limit their effectiveness and practicality in emergency situations and various clinical settings.

[0011] Therefore, there is a need for a gel-type spray-type hemostatic agent that has a fast hemostasis rate, can be administered accurately and easily regardless of the site of use, is simple to use, and is reusable.

[0012] The present invention is intended to solve the above-mentioned problems, and provides a method for manufacturing a spray-type hemostatic agent by mixing gel-type kaolin and cellulose that can be quickly sprayed and used in an emergency situation, and a spray-type hemostatic agent manufactured thereby.

[0013] The present invention aims to provide a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose, which can be used quickly not only in cases of bleeding occurring in surgical fields such as surgical operations and trauma but also in other emergency situations, has a fast hemostasis speed, shortens the hemostasis time compared to existing hemostatic agents, and prevents situations in which patients are put at risk due to excessive bleeding, and provides a spray-type hemostatic agent manufactured thereby.

[0014] In addition, the technical problems to be achieved by the present invention are not limited to the technical problems mentioned above, and other technical problems not mentioned can be clearly understood by a person having ordinary skill in the technical field to which the present invention belongs from the description below.

[0015] In order to achieve the above-described purpose, the method for manufacturing a spray-type hemostatic agent mixed with kaolin and cellulose according to the present invention comprises the steps of mixing hyaluronic acid in sterile distilled water, mixing lecithin in the mixture, mixing kaolin and cellulose in the mixture, cooling the mixture, injecting the mixture into a spray-type container, and filling gas.

[0016] The step of mixing the hyaluronic acid is to stir the hyaluronic acid using an ultrasonic stirrer at 500 to 600 rpm for 15 to 20 minutes at 50 to 60°C.

[0017] The step of mixing the above lecithin is to stir the lecithin with a magnetic stirrer at 200 to 300 rpm for 30 to 40 minutes at 40 to 60°C.

[0018] It is important to maintain a pH of 5.5 to 6.5 during the step of mixing the lecithin.

[0019] The step of mixing the above kaolin and cellulose is to stir the kaolin and cellulose at 500 to 600 rpm using an ultrasonic stirrer at 60 to 70°C for 50 to 60 minutes.

[0020] And the step of mixing the kaolin and cellulose is characterized by mixing 0.1 to 5 parts by weight of hyaluronic acid, 0.1 to 1 part by weight of lecithin, 0.1 to 3 parts by weight of kaolin, and 4 to 8 parts by weight of cellulose with respect to 100 parts by weight of the sterilized distilled water.

[0021] The above cooling step involves stirring the mixture at 20°C to 25°C with a magnetic stirrer at 300 to 400 rpm for 30 to 40 minutes.

[0022] In order to achieve the above-mentioned purpose, a spray-type hemostatic agent mixed with kaolin and cellulose according to the present invention can be manufactured by any one of the above methods.

[0023] As described above, the present invention having the above-described configuration is manufactured so that a gel-type hemostatic agent can be sprayed and used, so that it is easy to use and can be used quickly in an emergency situation, and the hemostasis speed is fast, so that the hemostasis time can be shortened compared to existing hemostatic agents.

[0024] And by mixing hyaluronic acid and lecithin in addition to kaolin and cellulose, it has excellent hemostasis speed, rebleeding prevention rate, absorption rate, and application power, and is superior in tissue protection and infection prevention effect on the wound surface compared to existing injection-type and gel-type hemostatic agents, and has the effect of preventing situations where patients are at risk due to excessive bleeding.

[0025] Figure 1 is a flow chart showing step-by-step the method for manufacturing a spray-type hemostatic agent mixed with kaolin and cellulose of the present invention.

[0026] Figure 2 is a drawing showing the results of a hemostasis speed test according to examples and comparative examples of a spray-type hemostatic agent manufactured according to a method for manufacturing a spray-type hemostatic agent mixing kaolin and cellulose of the present invention.

[0027] Figure 3 is a drawing showing the results of a test for preventing rebleeding according to examples and comparative examples of a spray-type hemostatic agent manufactured according to a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose of the present invention.

[0028] Figure 4 is a drawing showing the results of an absorption rate test according to examples and comparative examples of a spray-type hemostatic agent manufactured according to a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose of the present invention.

[0029] FIG. 5 is a drawing showing the results of a coating force test according to examples and comparative examples of a spray-type hemostatic agent manufactured according to a method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose of the present invention.

[0030] The advantages and features of the present invention and the method for achieving them will become clear with reference to the embodiments described in detail below together with the accompanying drawings.

[0031] However, the present invention is not limited to the embodiments disclosed below, but may be implemented in various different forms.

[0032] The embodiments herein are provided to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the invention.

[0033] And, the present invention is defined only by the scope of the claims.

[0034] Accordingly, in some embodiments, well-known components, well-known operations, and well-known techniques are not specifically described to avoid obscuring the present invention.

[0035] Additionally, throughout the specification, the same reference numerals refer to the same components, and the terminology used (referred to) in this specification is for the purpose of describing embodiments and is not intended to limit the present invention.

[0036] In this specification, the singular includes the plural unless specifically stated otherwise in the phrase, and the reference to an element or action as “including (or comprising)” does not exclude the presence or addition of one or more other elements or actions.

[0037] Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in a meaning that can be commonly understood by a person of ordinary skill in the art to which the present invention belongs.

[0038] Additionally, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless they are defined otherwise.

[0039] Hereinafter, a preferred embodiment of the present invention will be described with reference to the attached drawings.

[0040] Referring to FIGS. 1 to 5, the method for manufacturing a spray-type hemostatic agent mixed with kaolin and cellulose according to the present invention is as follows.

[0041] First, add hyaluronic acid to the sterilized distilled water in the mixing tank and mix (S10).

[0042] Hyaluronic acid is a type of polysaccharide called glycosaminoglycan (GAG), abundantly found in our skin, joints, cartilage, and eyes. Known for its exceptional moisturizing properties, hyaluronic acid plays a crucial role in various biological functions, including maintaining skin elasticity, reducing wrinkles, and lubricating joints.

[0043] Hyaluronic acid is known to bind to receptors on the surface of platelets and promote platelet aggregation. Platelet aggregation plays a crucial role in blood clotting and helps prevent bleeding. Hyaluronic acid acts as a vasoconstrictor, constricting blood vessels at the site of bleeding and helping reduce the amount of bleeding.

[0044] At this time, when mixing hyaluronic acid in sterilized distilled water, stir at 50 to 60°C with an ultrasonic stirrer at 500 to 600 rpm for 15 to 20 minutes.

[0045] Ultrasonic energy creates microscopic vibrations within the mixture, helping to evenly disperse the hyaluronic acid molecules. This reduces turbidity, prevents clumping, and improves product quality.

[0046] Ultrasonic energy can cleave hyaluronic acid molecular chains, reducing their molecular weight. This reduces hyaluronic acid's viscosity, promotes skin absorption, and can be useful in formulation development. This sonication can enhance the bioactivity of hyaluronic acid.

[0047] The temperature range of 50°C to 60°C is optimal for maximizing solubility while minimizing hyaluronic acid degradation. Too low a temperature can impede dissolution, while too high a temperature can degrade hyaluronic acid. Furthermore, it was observed that when the stirring temperature was lower than 50°C, the hemostatic agent was not sprayed properly or clumped together.

[0048] The above ultrasonic stirrer has both an ultrasonic frequency-based stirring function and a magnetic stirring function. A speed of 500 to 600 rpm is an appropriate speed that effectively disperses hyaluronic acid molecules while minimizing the temperature rise of the solution. It takes 15 to 20 minutes to sufficiently disperse most hyaluronic acid molecules. It was found that when the stirring speed is lower than 500 rpm, the hemostatic agent is not evenly distributed to the wound area even when sprayed, and the sprayed hemostatic agent clumps together. In addition, when the stirring speed is faster than 600 rpm, there is a problem of damage to the hyaluronic acid.

[0049]

[0050] Add lecithin to the mixture (S20).

[0051] Lecithin, a type of phospholipid that is a major component of cell membranes in our bodies, is known to possess various biological activities. Lecithin is known to bind to receptors on the surface of platelets and promote platelet aggregation. Platelet aggregation plays a crucial role in blood clotting and helps prevent bleeding. Lecithin acts as a vasoconstrictor, constricting blood vessels at the site of bleeding and helping reduce the amount of bleeding.

[0052] Lecithin has anti-inflammatory properties, helping to alleviate inflammation that occurs during the hemostasis process. Because lecithin is a substance naturally produced in our bodies, it is highly biocompatible and safe.

[0053] At this time, lecithin is stirred with a magnetic stirrer at 200 to 300 rpm for 30 to 40 minutes at 40 to 60°C.

[0054] The temperature range of 40°C to 60°C is ideal for increasing lecithin solubility and maintaining a stable dispersion. Too low a temperature can impede lecithin dissolution, while too high a temperature can decompose it.

[0055] A speed of 200 to 300 rpm is an appropriate speed to effectively disperse lecithin while minimizing the temperature rise of the solution.

[0056] A stirring speed below 200 rpm will interfere with the dispersion of the lecithin, and a speed that is too fast can cause the solution temperature to rise excessively. 30 to 40 minutes is sufficient to disperse most lecithin.

[0057] And it is important to maintain a pH of 5.5 to 6.5 while mixing lecithin.

[0058] Lecithin is most stable in a slightly acidic range (pH 5.5–6.5). Outside of this range, it can decompose or denature. Lecithin acts as an emulsion stabilizer, and a pH of 5.5–6.5 is essential for stable emulsions. Acids or bases can be added during lecithin mixing to maintain a pH of 5.5–6.5.

[0059]

[0060] Kaolin and cellulose are mixed into the mixture (S30).

[0061] Kaolin is a naturally occurring hydrous aluminum silicate, white or milky white powder, with a chemical composition of Al2Si2O5(OH)4 containing pyrophyllite.

[0062] This kaolin can promote blood clotting by interacting with Factor XII (Hageman Factor), a plasma protein present in the blood.

[0063] Additionally, kaolin plays a role in causing transformation by activating Factor XII, Factor XI (thromboplastin precursor), and prekallikrein.

[0064] In particular, Factor XII is involved in activation, and kaolin increases the sensitivity of kallikreene, a plasma component of Factor XII, significantly accelerating the activation rate, thereby promoting blood coagulation and improving the hemostatic effect of wounds.

[0065] Cellulose is a natural polymeric carbohydrate composed of D-glucose units linked by β-1,4-linkages. Cellulose fibers bind to the surface of platelets, promoting platelet aggregation and activating blood clotting factors, thus promoting clot formation. Cellulose possesses high absorbency, absorbing blood and body fluids at the site of bleeding, thereby aiding clot formation and minimizing blood loss.

[0066] Kaolin and cellulose exhibit hemostatic effects through the following mechanisms:

[0067] Kaolin binds to the surface of platelets, promoting platelet aggregation and activating blood clotting factors to promote clot formation. Kaolin's high absorbency absorbs blood and body fluids at the site of bleeding, aiding clot formation and minimizing blood loss. Cellulose suppresses inflammation and promotes tissue regeneration, aiding wound healing after hemostasis.

[0068] A higher kaolin content results in faster blood coagulation and greater absorbency. However, the hemostatic agent may become too hard, making it difficult to apply to the wound. A higher cellulose content improves the flexibility and biocompatibility of the hemostatic agent. However, this can reduce blood coagulation and absorbency.

[0069] At this time, kaolin and cellulose are stirred with an ultrasonic stirrer at 500 to 600 rpm for 50 to 60 minutes at 60 to 70°C.

[0070] Temperatures below 60°C may result in reduced mixing efficiency, while temperatures above 70°C may result in the decomposition of kaolin or cellulose. Ultrasonic agitation itself can cause a temperature increase, so the temperature must be continuously monitored and adjusted as needed.

[0071] In addition, it was discovered that when the stirring temperature is lower than 60℃, the hemostatic agent is not evenly distributed to the wound area even when sprayed, but is sprayed in clumps.

[0072] The above ultrasonic stirrer has both a stirring function using ultrasonic frequency and a magnetic stirring function. If the stirring speed is slower than 500 rpm, the mixing is uneven, and if the stirring speed is faster than 600 rpm, there is a problem that the cellulose fibers are damaged.

[0073] Be careful not to stir for more than 60 minutes, as excessive stirring can damage the cellulose fibers.

[0074]

[0075] The composition ratios of these ideal mixtures are as follows:

[0076] For 100 parts by weight of sterilized distilled water, mix 0.1 to 5 parts by weight of hyaluronic acid, 0.1 to 1 part by weight of lecithin, 0.1 to 3 parts by weight of kaolin, and 4 to 8 parts by weight of cellulose.

[0077] Sterile distilled water is the basic solvent of hemostatic agents, dissolving other ingredients and maintaining the formulation. Hyaluronic acid has minimal effect at concentrations below 0.1, and the formulation may become unstable at concentrations exceeding 5. Lecithin may separate at concentrations below 0.1, and may irritate the skin at concentrations exceeding 1. Kaolin has minimal effect at concentrations below 0.1, and the formulation may become thick and difficult to spray at concentrations exceeding 3. Cellulose may not maintain its shape and become runny at concentrations below 4, and may become difficult to spray at concentrations exceeding 8.

[0078]

[0079] Cool the mixture (S40).

[0080] Specifically, the mixture is stirred at 300 to 400 rpm with a magnetic stirrer at 20 to 25°C for 30 to 40 minutes. Caution should be exercised when the stirring speed exceeds 400 rpm, as the mixture may not cool uniformly or some components may coagulate. In addition, when the stirring time exceeds 40 minutes, excessive stirring may cause bubbles to form, which may deteriorate the quality of the mixture.

[0081] In addition, it was discovered that if the stirring speed is less than 300 rpm and the stirring time is less than 30 minutes, the hemostatic agent is not evenly distributed to the wound area and is sprayed in clumps.

[0082] A water bath or cooler may also be used for cooling.

[0083]

[0084] Inject into a spray-type container (S50).

[0085] Choose a spray bottle that is airtight and durable. To prevent contamination, sterilize the spray bottle before use.

[0086]

[0087] Fill with gas (S60).

[0088] Filling the spray bottle with gas increases the pressure inside the spray bottle, allowing for an even spraying of the hemostatic agent. The gas inside the spray bottle maintains a constant pressure, allowing the user to dispense the desired amount of hemostatic agent. Gas-filled spray bottles are convenient to carry and can be easily used in a variety of environments.

[0089]

[0090] Finally, it is packaged and sterilized.

[0091] Appropriate packaging materials must be selected to maintain the product's sterility even after sterilization. The sterilization process must completely eliminate all forms of microorganisms to ensure complete sterilization. After sterilization, packaged products must be stored in a clean environment.

[0092]

[0093] Examples and Comparative Examples

[0094] Hereinafter, the present invention will be specifically described with examples and comparative examples. Those skilled in the art will appreciate that the present invention can be modified in various ways beyond the compositions described in the examples below. The following examples are intended to exemplify the present invention and should not be construed as limiting the scope of the technical ideas of the present invention to the scope of the examples below.

[0095]

[0096] Example 1

[0097] Add 3g of hyaluronic acid to 100g of distilled tangerine water in a mixing tank and stir at 550rpm for 20 minutes using an ultrasonic stirrer at 55℃. Next, add 1g of lecithin and stir at 250rpm for 40 minutes using a magnetic stirrer at 50℃. While stirring the lecithin, monitor the pH value in real time using a pH meter to ensure that the pH is maintained at 6.

[0098] Then, 2 g of kaolin and 6 g of cellulose are stirred at 550 rpm for 55 minutes using an ultrasonic stirrer at 65°C. Then, the mixture is stirred at 350 rpm for 35 minutes using a magnetic stirrer at 20°C and cooled.

[0099] After cooling, the mixture is injected into a spray-type container that has been sterilized using plasma. The container is then filled with gas.

[0100]

[0101] Example 2

[0102] The same procedure as Example 1 was followed, except that 5 g of kaolin and 2 g of cellulose were added and mixed.

[0103]

[0104] Comparative Example 1

[0105] Lecithin was not mixed, 4 g of hyaluronic acid was added, and the rest was performed in the same manner as in Example 1.

[0106]

[0107] Comparative Example 2

[0108] Hyaluronic acid was not mixed, 8 g of cellulose was added, and the rest was performed in the same manner as in Example 1.

[0109]

[0110] Comparative Example 3

[0111] Without mixing cellulose, 5 g of hyaluronic acid was added, and the rest was performed in the same manner as in Example 1.

[0112]

[0113] [Experimental Example]

[0114] Hemostasis rate test

[0115] Twelve-week-old SD male rats were anesthetized with avertin. After anesthesia, the femoral artery was transected to induce bleeding. A hemostatic agent was sprayed onto the bleeding site and pressure was applied. The time until bleeding stopped was measured with a stopwatch. The average time to hemostasis was calculated using multiple samples.

[0116]

[0117] Rebleeding prevention rate test

[0118] Twelve-week-old SD male rats were anesthetized with avertin. The femoral artery was transected to induce bleeding. A hemostatic agent was applied to the bleeding site and pressure was applied to stop the bleeding. After hemostasis, the surgical site was observed at regular intervals to record whether rebleeding occurred. The percentage of patients who did not experience rebleeding was calculated.

[0119]

[0120] Absorption rate test

[0121] Twelve-week-old SD male rats were anesthetized with avertin. Blood was collected using a cardiac blood collection method. The blood was placed in a tube containing an absorbable hemostatic agent. After a certain period of time, the amount of blood remaining in the tube was measured to calculate the amount of blood absorbed by the hemostatic agent. The average absorption rate was calculated using multiple samples.

[0122]

[0123] Application power test

[0124] Twelve-week-old SD male rats were anesthetized with avertin. The femoral artery was transected to induce bleeding. A hemostatic agent was applied to the bleeding site. After application, the hemostatic agent was observed to ensure even distribution throughout the bleeding area. The consistency of the application was assessed using multiple samples.

[0125]

[0126] [Experimental Results]

[0127] Referring to Figure 2, the hemostasis speed was faster in the order of Example 1, Example 2, and Comparative Example 2, confirming that kaolin and cellulose were effective in hemostasis. The fact that Comparative Example 2 had a better hemostasis speed than Comparative Example 1 suggests that cellulose had a better effect on hemostasis than hyaluronic acid. Comparative Example 3 appeared to have a slower hemostasis speed because cellulose was not mixed in.

[0128] It was confirmed that Example 1 had a better hemostasis speed than Example 2 and Comparative Example 2.

[0129] That is, it is clear that kaolin and cellulose are important components for hemostasis, but it can be seen that the mixing ratio of hyaluronic acid, lecithin, kaolin, and cellulose is important.

[0130]

[0131] Referring to Figure 3, it was confirmed that the presence or absence of cellulose was important in the prevention of rebleeding. The fact that Comparative Example 2 showed a better rebleeding prevention rate than Example 2 and Comparative Example 1 appears to be due to the addition of a large amount of cellulose without mixing in hyaluronic acid.

[0132] Comparative Example 1 added both cellulose and hyaluronic acid, while Comparative Example 2 did not add hyaluronic acid and instead added more cellulose. Ultimately, it appears that cellulose is more effective in preventing rebleeding.

[0133] Comparative Example 3 did not mix cellulose, so the effect of preventing rebleeding was relatively low.

[0134] However, considering that the rebleeding prevention effect of Example 1 is good, the content of cellulose is also important, but kaolin and hyaluronic acid also seem to have a good effect in preventing rebleeding, and it can be seen that the mixing ratio of each component is important when mixing hyaluronic acid, lecithin, kaolin, and cellulose.

[0135]

[0136] Referring to Figure 4, it appears that cellulose also played an important role in the absorption rate. Comparative Example 2 added a large amount of cellulose without mixing in hyaluronic acid, and the absorption rate was better than that of Comparative Example 1, which added both hyaluronic acid and cellulose, indicating that cellulose had a better absorption effect than hyaluronic acid.

[0137] Comparative Example 3 showed a relatively low absorption rate by adding hyaluronic acid without adding cellulose.

[0138] However, considering that the absorption rate effect of Example 1 is good, the content of cellulose is important, but kaolin and hyaluronic acid also seem to have a good effect on the absorption rate, and it can be seen that the mixing ratio of each component is important when mixing hyaluronic acid, lecithin, kaolin, and cellulose.

[0139]

[0140] Referring to Figure 5, lecithin was found to play a significant role in enhancing the application power of the hemostatic agent. Cellulose also showed good results.

[0141] Comparative Example 1 had poor spreading power because lecithin was not mixed. Comparative Example 2 mixed cellulose without mixing hyaluronic acid, and Comparative Example 3 mixed hyaluronic acid without mixing cellulose. As a result, it was confirmed that cellulose had a better effect on spreading power than hyaluronic acid.

[0142] Example 2 mixed more kaolin and less cellulose compared to Example 1, and it was found that cellulose was more important than kaolin in terms of application power.

[0143] And, as in Example 1, hyaluronic acid, lecithin, kaolin, and cellulose were mixed, and it was confirmed that the mixing ratio of each component was important.

[0144]

[0145] While the present invention has been illustrated and described with reference to specific embodiments thereof, it will be readily apparent to those skilled in the art that various modifications and variations may be made therein without departing from the spirit and scope of the invention as set forth in the appended claims.

Claims

1. Step of mixing hyaluronic acid into sterilized distilled water (S10); Step of mixing lecithin into the above mixture (S20); Step of mixing kaolin and cellulose into the above mixture (S30); Step of cooling the above mixture (S40); Step of injecting into a spray-type container (S50); and A method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that it includes a step of filling gas (S60).

2. In claim 1, The step of mixing the above hyaluronic acid (S10) is as follows: A method for producing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that hyaluronic acid is stirred at 50 to 60°C with an ultrasonic stirrer at 500 to 600 rpm for 15 to 20 minutes.

3. In claim 1, The step of mixing the above lecithin (S20) is as follows: A method for producing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that lecithin is stirred with a magnetic stirrer at 200 to 300 rpm for 30 to 40 minutes at 40 to 60°C.

4. In claim 3, The step of mixing the above lecithin (S20) is as follows: A method for manufacturing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that the pH is maintained at 5.5 to 6.5 while mixing lecithin.

5. In claim 1, The step of mixing the above kaolin and cellulose (S30) is as follows: A method for producing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that the kaolin and cellulose are stirred with an ultrasonic stirrer at 500 to 600 rpm for 50 to 60 minutes at 60 to 70°C.

6. In claim 5, The step of mixing the above kaolin and cellulose (S30) is as follows: A method for producing a spray-type hemostatic agent mixed with kaolin and cellulose, characterized in that 0.1 to 5 parts by weight of hyaluronic acid, 0.1 to 1 part by weight of lecithin, 0.1 to 3 parts by weight of kaolin, and 4 to 8 parts by weight of cellulose are mixed with 100 parts by weight of the above sterilized distilled water.

7. In claim 1, The above cooling step (S40) is A method for producing a spray-type hemostatic agent by mixing kaolin and cellulose, characterized in that the mixture is stirred with a magnetic stirrer at 300 to 400 rpm for 30 to 40 minutes at 20 to 25°C.

8. A spray-type hemostatic agent mixed with kaolin and cellulose, characterized in that it is manufactured by the method of any one of claims 1 to 7.

Images